Radiolanthanides Device Production
World Journal of Nuclear Science and Technology · 2015 · 05 (02) · 111-119
DOI: 10.4236/wjnst.2015.52011 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Nuclear Science and Technology, 2015. Verfasst von F. Monroy-Guzman und 3 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
149Pm, 166Ho, 161Tb and 177Lu conjugated to chemical agents (monoclonal antibodies, polypeptide, etc.) have the appropriate decay characteristics for imaging and therapeutic studies and consequently the potential to be useful in radiotherapy and diagnosis. These carrier-free radioisotopes can be produced by neutron irradiation of a lanthanide target followed by β- decay, and a posterior radiochemical separation of the daughter radionuclide from macro-amounts of the parent target. In order to produce carrier free 149Pm, 161Tb, 166Ho and 177Lu for radiotherapy, with a radionuclide purity of more than 99.9%, a device production was developed based on separation of Nd/Pm, Gb/Tb, Dy/Ho and Yb/Lu by extraction chromatography.
Zitieren
APA
Monroy-Guzman, F., Barreiro, F. J., Salinas, E. J., & Treviño, A. L. V. (2015). Radiolanthanides Device Production. World Journal of Nuclear Science and Technology, 05(02), 111-119. https://doi.org/10.4236/wjnst.2015.52011
Vancouver
Monroy-Guzman F, Barreiro FJ, Salinas EJ, Treviño ALV. Radiolanthanides Device Production. World Journal of Nuclear Science and Technology. 2015;05(02):111-119. doi:10.4236/wjnst.2015.52011
BibTeX
@article{MonroyGuzman2015,
author = {Monroy-Guzman, F. and Barreiro, F. Jimenez and Salinas, E. Jaime and Treviño, A. L. Vera},
title = {Radiolanthanides Device Production},
journal = {World Journal of Nuclear Science and Technology},
year = {2015},
volume = {05},
number = {02},
pages = {111--119},
doi = {10.4236/wjnst.2015.52011}
}
EUVIMED